Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2024

Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2024



DelveInsight’s, “Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2024” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Beta Selective Thyroid Hormone Receptor Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Beta Selective Thyroid Hormone Receptor Agonist Understanding

Beta Selective Thyroid Hormone Receptor Agonist: Overview

Thyroid hormones (THs) elicit significant effects on numerous physiological processes, such as growth, development, and metabolism. A lack of thyroid hormones is not compatible with normal health. Most THs effects are mediated by two different thyroid hormone receptor (TR) isoforms, namely TRα and TRβ, with the TRβ isoform known to be responsible for the main beneficial effects of TH on liver. In brain, despite the crucial role of TRα isoform in neuronal development, TRβ has been proposed to play a role in the remyelination processes. TRβ is the predominant isoform of TR in the liver and therefore is primarily responsible for the reduction of cholesterol levels, whereas the adverse effects on heart and bone are mainly connected to TRα. Thus, in the development of clinically useful drug candidates, much effort has been directed toward the design of compounds with isomer-specific activity related to the structure of thyroid hormones, i.e., thyromimetics that are liver and/or TRβ selective.

""Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Beta Selective Thyroid Hormone Receptor Agonist pipeline landscape is provided which includes the disease overview and Beta Selective Thyroid Hormone Receptor Agonist treatment guidelines. The assessment part of the report embraces, in depth Beta Selective Thyroid Hormone Receptor Agonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Beta Selective Thyroid Hormone Receptor Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Beta Selective Thyroid Hormone Receptor Agonist R&D. The therapies under development are focused on novel approaches to treat/improve Beta Selective Thyroid Hormone Receptor Agonist.
Beta Selective Thyroid Hormone Receptor Agonist Emerging Drugs Chapters

This segment of the Beta Selective Thyroid Hormone Receptor Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Beta Selective Thyroid Hormone Receptor Agonist Emerging Drugs
  • Resmetirom: Madrigal Pharmaceuticals
Resmetirom (MGL-3196) is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist. Preclinical, toxicology, Phase I, and Phase II clinical data suggest resmetirom has an attractive, differentiated profile as a potential treatment for non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) and associated dyslipidemias. It is currently in Phase III stage of development.
  • VK2809: Viking Therapeutics
VK2809 is an orally available small molecule agonist of the thyroid hormone receptor that possesses selectivity for liver tissue, as well as the beta receptor subtype, and has demonstrated promising therapeutic potential in a range of lipid disorders, including NASH.

Further product details are provided in the report……..

Beta Selective Thyroid Hormone Receptor Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Beta Selective Thyroid Hormone Receptor Agonist drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Beta Selective Thyroid Hormone Receptor Agonist
There are approx. 14+ key companies which are developing the therapies for Beta Selective Thyroid Hormone Receptor Agonist. The companies which have their Beta Selective Thyroid Hormone Receptor Agonist drug candidates in the most advanced stage, i.e. Phase III include, Madrigal Pharmaceuticals.
  • Phases
DelveInsight’s report covers around 14+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Beta Selective Thyroid Hormone Receptor Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Beta Selective Thyroid Hormone Receptor Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Beta Selective Thyroid Hormone Receptor Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Beta Selective Thyroid Hormone Receptor Agonist drugs.

Beta Selective Thyroid Hormone Receptor Agonist Report Insights
  • Beta Selective Thyroid Hormone Receptor Agonist Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Beta Selective Thyroid Hormone Receptor Agonist Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Beta Selective Thyroid Hormone Receptor Agonist drugs?
  • How many Beta Selective Thyroid Hormone Receptor Agonist drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Beta Selective Thyroid Hormone Receptor Agonist?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Beta Selective Thyroid Hormone Receptor Agonist therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Beta Selective Thyroid Hormone Receptor Agonist and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Madrigal Pharmaceuticals
  • Ascletis
  • Eccogene
  • Viking Therapeutics
  • Aligos Therapeutics
  • Autobahn Therapeutics
  • Terns Pharmaceuticals
  • Viking Therapeutics
Key Products
  • Resmetirom
  • ASC-41
  • Research programme: thyroid hormone receptor beta agonists
  • VK2809
  • ALG-055009
  • ABX-002
  • TERN-501
  • VK 0214


Introduction
Executive Summary
Beta Selective Thyroid Hormone Receptor Agonist: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Resmetirom: Madrigal Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
VK2809: Viking Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
ASC-41: Ascletis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
Comparative Analysis
ALG-055009: Aligos Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Beta Selective Thyroid Hormone Receptor Agonist Key Companies
Beta Selective Thyroid Hormone Receptor Agonist Key Products
Beta Selective Thyroid Hormone Receptor Agonist- Unmet Needs
Beta Selective Thyroid Hormone Receptor Agonist- Market Drivers and Barriers
Appendix

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings